Mycophenolate Mofetil Teva

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Teva, is an antimetabolite immunosuppressant presented as an oral tablet for oral use. It helps prevent organ transplant rejection and treats certain autoimmune diseases such as lupus nephritis.

GNH USA supplies Mycophenolate Mofetil Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is used in conditions that involve immune‑mediated tissue injury or autoimmunity.

- Organ transplant rejection: reduces the risk of acute and chronic graft rejection by inhibiting lymphocyte proliferation. - Lupus nephritis: controls renal inflammation and helps preserve kidney function in systemic lupus erythematosus. - Other autoimmune disorders: provides immunosuppression for diseases where T‑ and B‑cell activity drives pathology.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea and vomiting: gastrointestinal discomfort that may improve with food. - Diarrhea: frequent loose stools, sometimes requiring fluid replacement. - Headache: mild to moderate intensity. - Tremor: fine shaking of the hands or limbs. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Infections: increased susceptibility to bacterial, viral or fungal infections. - Bone marrow suppression: leukopenia, anemia or thrombocytopenia. - Malignancy: heightened risk of lymphoproliferative disorders. - Severe liver injury: elevated transaminases or hepatitis. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease.

Before initiating therapy, clinicians should assess baseline health status and monitor patients regularly.

- Monitor blood counts: perform complete blood count to detect leukopenia or anemia. - Assess renal function: check serum creatinine and eGFR, especially in transplant recipients. - Avoid use in pregnancy: potential teratogenic effects require contraception for women of child‑bearing potential. - Evaluate infection risk: screen for latent infections and vaccinate before treatment when possible. - Adjust dose in hepatic impairment: consider reduced exposure in patients with liver dysfunction. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mycophenolate Mofetil can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Live vaccines: may cause uncontrolled infection due to immunosuppression. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce mycophenolate exposure. - Antacids containing aluminum or magnesium: decrease absorption when taken simultaneously.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: combined use may increase risk of hyperkalemia and renal dysfunction. - Warfarin: may alter INR, requiring more frequent coagulation monitoring. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can exacerbate nephrotoxicity, especially in patients with compromised kidney function.